Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
In the latest session, Dr. Reddy’s Laboratories Ltd. ADR (NYSE: RDY) closed at $14.44 down -0.48% from its previous closing price of $14.51. In other words, the price has decreased by -$0.48 from its previous closing price. On the day, 0.86 million shares were traded. RDY stock price reached its highest trading level at $14.65 during the session, while it also had its lowest trading level at $14.405.
Ratios:
For a deeper understanding of Dr. Reddy’s Laboratories Ltd. ADR’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 15.46 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 87.71. For the most recent quarter (mrq), Quick Ratio is recorded 1.36 and its Current Ratio is at 1.89. In the meantime, Its Debt-to-Equity ratio is 0.14 whereas as Long-Term Debt/Eq ratio is at 0.01.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RDY now has a Market Capitalization of 12270782464 and an Enterprise Value of -2328564992. As of this moment, Dr.’s Price-to-Earnings (P/E) ratio for their current fiscal year is 18.07, and their Forward P/E ratio for the next fiscal year is 22.74. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.06 while its Price-to-Book (P/B) ratio in mrq is 2.95. Its current Enterprise Value per Revenue stands at -0.007 whereas that against EBITDA is -0.026.
Stock Price History:
The Beta on a monthly basis for RDY is 0.40, which has changed by -0.09670961 over the last 52 weeks, in comparison to a change of 0.15535986 over the same period for the S&P500. Over the past 52 weeks, RDY has reached a high of $16.19, while it has fallen to a 52-week low of $12.26. The 50-Day Moving Average of the stock is 0.72%, while the 200-Day Moving Average is calculated to be 1.43%.
Shares Statistics:
For the past three months, RDY has traded an average of 1.18M shares per day and 842560 over the past ten days. A total of 834.58M shares are outstanding, with a floating share count of 832.34M. Insiders hold about 0.00% of the company’s shares, while institutions hold 13.22% stake in the company. Shares short for RDY as of 1756425600 were 9459567 with a Short Ratio of 8.01, compared to 1753920000 on 9892750. Therefore, it implies a Short% of Shares Outstanding of 9459567 and a Short% of Float of 2.21.
Dividends & Splits
According to the company, the forward annual dividend rate for RDY is 0.09, from 8.0 in the trailing year. Against a Trailing Annual Dividend Yield of 0.5513439. The stock’s 5-year Average Dividend Yield is 0.72. The current Payout Ratio is 8.90% for RDY, which recently paid a dividend on 2025-07-25 with an ex-dividend date of 2025-07-25. Stock splits for the company last occurred on 2024-11-05 when the company split stock in a 5:1 ratio.
Earnings Estimates
Analysts are recommending an EPS of between $68.43 and $68.43 for the fiscal current year, implying an average EPS of $68.43. EPS for the following year is $54.78, with 1.0 analysts recommending between $54.78 and $54.78.
Revenue Estimates
A total of 4 analysts believe the company’s revenue will be $88.11B this quarter.It ranges from a high estimate of $90.33B to a low estimate of $86.32B. As of. The current estimate, Dr. Reddy’s Laboratories Ltd. ADR’s year-ago sales were $80.16BFor the next quarter, 4 analysts are estimating revenue of $84.87B. There is a high estimate of $89.02B for the next quarter, whereas the lowest estimate is $81.82B.
A total of 37 analysts have provided revenue estimates for RDY’s current fiscal year. The highest revenue estimate was $364.68B, while the lowest revenue estimate was $329.41B, resulting in an average revenue estimate of $344.04B. In the same quarter a year ago, actual revenue was $325.54BBased on 36 analysts’ estimates, the company’s revenue will be $349.15B in the next fiscal year. The high estimate is $385.09B and the low estimate is $325.4B.
